Profile of serogroup Y meningococcal infections in Canada: Implications for vaccine selection

Canadian Journal of Infectious Diseases and Medical Microbiology

Volumn 20, Issue 4, 2009, Pages

  Le Saux, Nicole ^a   Bettinger, Julie A ^b   Wootton, Susan ^c   Halperin, Scott A ^d   Vaudry, Wendy ^e   Scheifele, David W ^b   Tsang, Raymond ^f  

^a CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF TEXAS   (United States)

^d DALHOUSIE UNIVERSITY   (Canada)

^e UNIVERSITY OF ALBERTA   (Canada)

^f PUBLIC HEALTH AGENCY OF CANADA   (Canada)

Author keywords

Invasive meningococcal disease; Meningococcal vaccine; Morbidity; Mortality; Neisseria meningitides; Serogroups A, C, Y, W135

Indexed keywords

MENINGOCOCCUS VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANADA; CEREBROSPINAL FLUID CULTURE; CHILD; FEMALE; HUMAN; IMMUNIZATION; INFANT; MAJOR CLINICAL STUDY; MALE; MENINGOCOCCOSIS; MORTALITY; NEISSERIA MENINGITIDIS; NONHUMAN; POLYMERASE CHAIN REACTION; PREDICTION; SEROTYPE; VACCINATION; VIRUS ISOLATION;

EID: 73949143401     PISSN: 17129532     EISSN: None     Source Type: Journal    
DOI: 10.1155/2009/871071     Document Type: Article

References (23)

1. Tsang RS, Law DK, Henderson AM, Blake ML, Stoltz J. Increase in serogroup C meningococcal disease in Canada is associated with antigenic changes in the protein antigens of the ET-15 clone of Neisseria meningitidis. J Infect Dis 2006;194:1791-2.
2. De Wals P. Immunization strategies for the control of serogroup C meningococcal disease in developed countries. Expert Rev Vaccines 2006;5:269-75.
3. De Wals P, Deceuninck G, Boulianne N, De SG. Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine. JAMA 2004;292:2491-4.
4. Tyrrell GJ, Chui L, Johnson M, Chang N, Rennie RP, Talbot JA. Outbreak of Neisseria meningitidis, Edmonton, Alberta, Canada. Emerg Infect Dis 2002;8:519-21.
5. Squires SG, Deeks SL, Tsang RS. Enhanced surveillance of invasive meningococcal disease in Canada: 1 January, 1999, through 31 December, 2001. Can Commun Dis Rep 2004;30:17-28.
6. Patrick DM, Champagne S, Goh SH, et al. Neisseria meningitidis carriage during an outbreak of serogroup C disease. Clin Infect Dis. 2003;37:1183-8.
7. Bettinger JA, Scheifele DW, Le Saux N, Halperin SA, Vaudry W, Tsang R; the members of the Canadian Immunization Monitoring Program, Active (IMPACT). The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada. Pediatr Infect Dis J 2009;28:220-4.
8. Enhanced surveillance of invasive meningococcal disease in Canada: 1 January, 2004, through 31 December, 2005. Can Commun Dis Rep 2007;33:1-15.
9. Hoang LM, Thomas E, Tyler S, et al. Rapid and fatal meningococcal disease due to a strain of Neisseria meningitidis containing the capsule null locus. Clin Infect Dis 2005;40:e38-e42.
10. Balmer P, Borrow R, Miller E. Impact of meningococcal C conjugate vaccine in the UK. J Med Microbiol 2002;51:717-22.
11. Rosenstein NE, Perkins BA, Stephens DS, et al. The changing epidemiology of meningococcal disease in the United States, 1992-1996. J Infect Dis 1999;180:1894-901.
12. Harrison LH, Jolley KA, Shutt KA, et al. Antigenic shift and increased incidence of meningococcal disease. J Infect Dis 2006;193:1266-74.
13. McEllistrem MC, Kolano JA, Pass MA, et al. Correlating epidemiologic trends with the genotypes causing meningococcal disease, Maryland. Emerg Infect Dis 2004;10:451-6.
14. Gray SJ, Trotter CL, Ramsay ME, et al. Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: Contribution and experiences of the Meningococcal Reference Unit. J Med Microbiol 2006;55:887-96.
15. Trotter CL, Ramsay ME, Gray S, Fox A, Kaczmarski E. No evidence for capsule replacement following mass immunisation with meningococcal serogroup C conjugate vaccines in England and Wales. Lancet Infect Dis 2006;6:616-7.
16. Tsang RS, Henderson AM, Cameron ML et al. Genetic and antigenic analysis of invasive serogroup Y Neisseria meningitidis isolates collected from 1999 to 2003 in Canada. J Clin Microbiol 2007;45:1753-8.
17. Racoosin JA, Whitney CG, Conover CS, Diaz PS. Serogroup Y meningococcal disease in Chicago, 1991-1997. JAMA 1998;280:2094-8.
18. Agudelo CI, Sanabria OM, Ovalle MV. Serogroup Y meningococcal disease, Columbia. Emerg Infect Dis 2008;14:990-1.
19. Jensen ES, Schonheyder HC, Lind I, Berthelsen L, Norgard B, Sorensen HT. Neisseria meningitidis phenotypic markers and septicaemia, disease progress and case-fatality rate of meningococcal disease: A 20-year population-based historical follow-up study in a Danish county. J Med Microbiol 2003;52:173-9.
20. Erickson L, De Wals P. Complications and sequelae of meningococcal disease in Quebec, Canada, 1990-1994. Clin Infect Dis 1998;26:1159-64.
21. Barquet N, Domingo P, Cayla JA, et al. Meningococcal disease in a large urban population (Barcelona, 1987-1992): Predictors of dismal prognosis. Barcelona Meningococcal Disease Surveillance Group. Arch Intern Med 1999;159:2329-40.
22. Booy R, Habibi P, Nadel S, et al. Reduction in case fatality rate from meningococcal disease associated with improved healthcare delivery. Arch Dis Child 2001;85:386-90.
23. Kaplan SL, Schutze GE, Leake JA, et al. Multicenter surveillance of invasive meningococcal infections in children. Pediatrics 2006;118:e979-e984.